Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JY306
- Development stage
- Phase 1
- Lead developer
- Jiangsu Provincial People's Hospital
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Injection
01
Overview
JY306 is an allogeneic, "off-the-shelf" (universal) natural killer (NK) cell therapy being developed for the treatment of CD70-positive malignant hematologic tumors. The therapy consists of NK cells engineered to target the CD70 antigen, which is highly expressed in various hematological malignancies, including acute myeloid leukemia (AML) and certain lymphomas, while having limited expression in normal tissues. As a "universal" NK cell product, JY306 is derived from healthy donors rather than the patient, potentially allowing for immediate availability and reduced manufacturing costs compared to autologous therapies. It is currently being evaluated in early-phase clinical trials to assess its safety, tolerability, and preliminary efficacy in patients with relapsed or refractory CD70+ hematological malignancies.
- Other names
- JY306 universal NK cell injectionJY-306 universal NK cell injectionJY 306 universal NK cell injectionJY306 Universal NK CellJY-306 Universal NK CellJY 306 Universal NK Cell
Beyond the preview
Go deeper on JY306.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JY306.